← Back to Calendar
Indication
Hematology / Hemostasis — Singapore
Key Notes
ISTH Congress 2026: June 22–26, Singapore. Premier thrombosis and hemostasis conference. Key data expected for hemophilia A programs including denecimig (Mim8, Novo Nordisk) and updates on emicizumab long-term data. Relevant ahead of Mim8 PDUFA ~July 2026 and to compare patient/physician positioning of competing hemophilia prophylaxis approaches.
⚠️ Not Investment Advice: This information is provided for educational purposes only.
PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period,
issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on
historical base rates and do not account for drug-specific factors. Always consult a financial advisor
before making investment decisions.
Discussion
Share your analysis, research, or questions about this catalyst. No account required.